No regrets as Lyell prepares for its first clinical trial
The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
Esmo 2021 – Mirati bids to be belle of the ball
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
